Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05024747 · ClinicalTrials.gov registry record · Phase 1
A Bioequivalence Study of 21 Milligram (mg) Nicotine Transdermal Patches (NicoDerm CQ, GlaxoSmithKline [GSK] Dungarvan) Compared to the Current Marketed 21 mg Nicotine Transdermal Patches (NicoDerm CQ, Alza) in Healthy Adult Smokers
A Phase 1 study, sponsored by HALEON.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT05024747 is a Phase 1 study that has completed, run by HALEON. The registered enrollment target is 22 participants.
The verdict
NCT05024747, a Phase 1 study, has completed, sponsored by HALEON.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the bioequivalence of the 21mg nicotine transdermal patch from GSK Dungarvan (Test) compared to the 21mg nicotine transdermal patch currently manufactured by Alza (Reference).
Interventions
- DRUG NicoDerm CQ patch (GSK Dungarvan)
- DRUG NicoDerm CQ (Alza)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2021-09-01 |
| Est. Completion | 2021-10-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05024747
The ClinicalTrials.gov registry entry for NCT05024747 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is HALEON, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which NicoDerm CQ patch (GSK Dungarvan) is the first listed.
NCT05024747 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05024747 about?
NCT05024747 is a clinical study titled "A Bioequivalence Study of 21 Milligram (mg) Nicotine Transdermal Patches (NicoDerm CQ, GlaxoSmithKline [GSK] Dungarvan) Compared to the Current Marketed 21 mg Nicotine Transdermal Patches (NicoDerm CQ, Alza) in Healthy Adult Smokers". The purpose of this study is to assess the bioequivalence of the 21mg nicotine transdermal patch from GSK Dungarvan (Test) compared to the 21mg nicotine transdermal patch currently manufactured by Alza (Reference).
What is the current status of trial NCT05024747?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2021-09-01. Estimated completion is 2021-10-25.
What interventions are being tested in trial NCT05024747?
The interventions under investigation include: NicoDerm CQ patch (GSK Dungarvan) (DRUG), NicoDerm CQ (Alza) (DRUG).
Who is sponsoring clinical trial NCT05024747?
This trial is sponsored by HALEON, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.